Cláudia Miranda and Mariana de Araújo Branco joined HiTech 2025 with AccelBio’s project OrganTech—a cutting-edge platform using hiPSC-derived organoids to accelerate preclinical studies and help reduce Phase 1 clinical trial risks. 

Through the programme, the team developed a dedicated business development plan to explore the market potential of AccelBio’s organoid platforms and reinforce how deep tech and biomedical innovation can address real industry needs. 

Interested in partnering around organoid-based models for efficacy and safety? Let’s talk.